Miflonide Breezhaler (Budesonide)

Budesonide, the active ingredient in Miflonide Breezhaler, is a corticosteroid presented as an inhalation powder for inhalation use. It is indicated for the management of asthma and chronic obstructive pulmonary disease in adults and children who require regular anti‑inflammatory therapy.

GNH USA supplies Miflonide Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Miflonide Breezhaler delivers budesonide to the airways, targeting inflammatory respiratory conditions.

- Asthma: reduces airway inflammation, improves symptom control and decreases the frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): lowers airway inflammation, helps prevent exacerbations and supports better lung function.

Miflonide Breezhaler may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Hoarseness or voice changes - Oral thrush (candidiasis) - Cough or throat irritation - Headache - Nasal congestion - Upper respiratory tract infection

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Paradoxical bronchospasm - Pneumonia - Decreased bone mineral density with long‑term use - Glaucoma or cataract formation - Suppression of adrenal function

Before using Miflonide Breezhaler, consider the following safety measures.

- Assess infection risk: avoid use during active respiratory infections unless prescribed. - Monitor growth in children: long‑term corticosteroid exposure may affect growth velocity. - Evaluate bone health: consider calcium/vitamin D supplementation for prolonged therapy. - Screen for glaucoma or cataracts: periodic ophthalmologic exams are advised. - Review concomitant medications: potential interactions may require dose adjustments. - Store at ambient temperature: keep below 25°C, in the original container, protected from moisture and direct sunlight.

Budesonide can interact with several drug classes; awareness helps prevent reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase systemic budesonide exposure. - Live vaccines: inhaled corticosteroids can diminish vaccine efficacy.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., itraconazole) at moderate potency: may modestly raise budesonide levels. - Diuretics: may increase risk of hypokalemia when combined with systemic corticosteroid effects. - Non‑selective beta‑blockers: may mask bronchospasm symptoms.